TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06401603
Drug: Listaftoclax
Normalized name: Lisaftoclax
DrugBank: Lisaftoclax (DB18054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06401603
Drug: Olverembatinib
Normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT05205850
Drug: RC118-ADC
Normalized name: dimethicone
DrugBank: RC118 (DB18428)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor
Study: NCT04980222
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intravenous (IV) glofitamab as per schedule specified in the treatment arm.
Study: NCT04980222
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
Study: NCT04980222
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 1.4 mg/m2 body surface area of vincristine IV as per schedule specified in the treatment arm.
Study: NCT04980222
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 100 mg of prednisone or prednisolone as per schedule specified in the treatment arm.
Study: NCT04980222
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 375 mg/m2 body surface area of rituximab IV as per schedule specified in the treatment arm.
Study: NCT05669313
Drug: Rivaroxaban 15 MG
Normalized name: rivaroxaban 15 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 15 mg after inclusion and on the morning after inclusion, i.e., before blood sampling
Study: NCT05312255
Drug: Beta-Adrenergic Antagonist
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive beta-blocker regimen as per SOC
Study: NCT05312255
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06002477
Drug: Mecamylamine Challenge
DrugBank: Mecamylamine (DB00657)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mecamylamine 20 mg oral pill administered once
Study: NCT05064878
Drug: ZX008 (Fenfluramine Hydrochloride)
Normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZX008 is supplied as an oral aqueous solution of Fenfluramine Hydrochloride.
Study: NCT05504239
Drug: Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
Normalized name: Teneligliptin (as teneligliptin hydrobromide) 20 mg oral tablet
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: To be orally administered once daily
Study: NCT05504239
Drug: Teneligliptin Placebo Oral Tablet
Normalized name: placebo Oral Tablet
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: To be orally administered once daily
Study: NCT06800183
Drug: Four-Chamber Tartrazine Patch across 3 Body Sites
Normalized name: tartrazine
DrugBank: Amber (DB14326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a chamber patch comprising four increasing doses of tartrazine (0.15M, 0.3M, 0.6M, 1.2M). This will be applied on the forearm, abdomen, and back to represent different skin thicknesses.
Study: NCT06210854
Drug: pBI-11
Normalized name: PBI-1402
DrugBank: PBI-1402 (DB05480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16/18 vaccine
Study: NCT06626568
Drug: Compound betamethasone Injection(Gluteal muscle injection)
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gluteal injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4
Study: NCT06626568
Drug: Compound betamethasone Injection(Subacromial Ultrasound Guided injection)
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound-guided subacromial injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4.
Study: NCT06698510
Drug: Arpraziquantel 150mg dispersible tablet
Normalized name: Disperse Blue 106
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arpraziquantel 150mg dispersible tablets given as single oral dose of 50mg/kg (in Kenya and Uganda; for Schistosoma mansoni infection) or 60mg/kg (in Côte d'Ivoire; for mixed infections with S. mansoni / S. haematobium) using weight-based dosing tables as detailed in the summary of product characteristics.
Study: NCT06146257
Drug: GLB-001
DrugBank: LB-001 (DB17685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally according to the assigned treatment schedule
Study: NCT03895567
Drug: A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral ceftriaxone~Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche).
Study: NCT03895567
Drug: B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal ceftriaxone formulations~Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule
Study: NCT03895567
Drug: C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal ceftriaxone formulations~Formulation 2 ceftriaxone 500mg + Na-CDC 125mg rectodispersible mannitol-based tablet
Study: NCT06525155
Drug: Triptorelin Embonate
Normalized name: Triptorelin embonate
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment 1: 3.75 mg twice before surgery (baseline and week-6) and once after surgery at week-12
Study: NCT06525155
Drug: Triptorelin Embonate
Normalized name: Triptorelin embonate
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment 2: 3.75 mg once after surgery at week-12
Study: NCT05933200
Drug: Triheptanoin
Normalized name: Triheptanoin
DrugBank: Triheptanoin (DB11677)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid for oral (PO) or enteral feeding tube administration
Study: NCT05354674
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AEM A：The specialist's decision to add bevacizumab to chemotherapy will be based on their own judgment~ARM B：The patient's PET/CT imaging, pathology, and clinical information were input into the signature, and the FOLFOX+Bevacizumab regimen was selected when the output label was 1. FOLFOXIRI chemotherapy regimen was selected when the output label was 0
Study: NCT04711122
Drug: Third generation cephalosporin antibiotics
Normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of antibiotic effect
Study: NCT06136442
Drug: Atogepant
Normalized name: Atogepant
DrugBank: Atogepant (DB16098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atogepant in real life in Italy
Study: NCT06514898
Drug: Td vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #5, #7 and #9.
Study: NCT06514898
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive PD-1 blockade IV starting with ACT continuing for up to 2 years as long as tolerable and without disease progression.
Study: NCT06368427
Drug: budesonide / glycopyrronium / formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension.~The COnCORD study is an observational study that will be conducted in a real-life setting in Romania and is not designed to evaluate medicinal products given according to a specific randomised schedule. Treatment with BGF MDI treatment prescribed as per current practice, according to the SmPC and local market reimbursement criteria
Study: NCT05269004
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab will be administered based on the dosage and administration received at the time of rollover from the Parent study.
Study: NCT05407675
Drug: BMS-986408
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05950945
Drug: Trastuzumab Deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug
Study: NCT04764448
Drug: Belcesiran
Normalized name: Belcesiran
DrugBank: Belcesiran (DB18226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.
Study: NCT04764448
Drug: Belcesiran
Normalized name: Belcesiran
DrugBank: Belcesiran (DB18226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.
Study: NCT05407675
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04764448
Drug: Belcesiran
Normalized name: Belcesiran
DrugBank: Belcesiran (DB18226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 96 weeks.
Study: NCT05593575
Drug: SPH3127+SPH3127matching placebo+valsartan matching placebo
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 tablet of SPH3127 (50 mg) ，3 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
Study: NCT05593575
Drug: SPH3127+SPH3127matching placebo+valsartan matching placebo
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 tablet of SPH3127 (50 mg) ，2 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
Study: NCT05593575
Drug: SPH3127+valsartan matching placebo
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 tablet of SPH3127 (50 mg) ， 1 capsule of valsartan matching placebo, orally, once daily for 12 consecutive weeks
Study: NCT05593575
Drug: SPH3127 matching placebo+valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 tablets of SPH3127 (50mg)matching placebo， 1 capsule of valsartan, orally, once daily for 12 consecutive weeks
Study: NCT06033703
Drug: Netarsudil Ophthalmic
Normalized name: netarsudil ophthalmic
DrugBank: Netarsudil (DB13931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical administration of Netarsudil
Study: NCT05873244
Drug: Zabadinostat (CXD101) and Geptanolimab
Normalized name: cytarabine and daunorubicin
DrugBank: Geptanolimab (DB16417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Zabadinostat (CXD101) at 20mg twice daily per orally Day 1-5 every 3 weeks~* Geptanolimab at 3mg/kg given intravenously every 2 weeks
Study: NCT05873244
Drug: Lenvatinib and Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clinicians' choice of TKI at corresponding recommended dosage:~* Lenvatinib at 8mg daily for patients with body weight \<60kg or 12mg daily with body weight ≥ 60kg~* Sorafenib at 400mg twice daily
Study: NCT05306275
Drug: CSL312
Normalized name: Immunoglobulin G4, anti-(human blood-coagulation factor viia) (human monoclonal CSL312 gamma4-chain), disulfide with human monoclonal CSL312 lambda-chain, dimer
DrugBank: Garadacimab (DB15629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factor XIIa antagonist monoclonal antibody for subcutaneous use
Study: NCT05561049
Drug: Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens
Study: NCT05891613
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml of 0.25% Bupivacaine (50 mg) with 20 ml of injectable saline (total of 40 cc) as a subcutaneous infiltration along the inframammary fold incision on one breast
Study: NCT05891613
Drug: Liposomal Bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml of Liposomal (Exparel) Bupivacaine (266 mg/20 ml) on the contralateral breast
Study: NCT05358249
Drug: trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MEK inhibitor, oral
Study: NCT05358249
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CDK4/6 inhibitor, oral
Study: NCT06222892
Drug: Camlipixant
Normalized name: Camlipixant
DrugBank: Camlipixant (DB19217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camlipixant will be administered.
Study: NCT03825965
Drug: MPL-001 (CBD: THC 25:1)
Normalized name: MPL
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25:1 cannabidiol (CBD): tetrahydrocannabinol (THC) oral formulation, with a concentration of 50 mg/mL CBD and 2 mg/mL THC, oil- Liquid for oral use
Study: NCT06492031
Drug: Icodextrin Peritoneal Dialysis Solution
Normalized name: Icodextrin Peritoneal Dialysis Solution
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment modality, treatment frequency, treatment dose, duration of dwell, and length of treatment, as determined and supervised by a prescribing physician experienced in treating ESRD with PD.
Study: NCT04727554
Drug: AMG 994
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an intravenous (IV) infusion.
Study: NCT04727554
Drug: AMG 404
Normalized name: Anti-pd-1 monoclonal antibody amg 404
DrugBank: AMG 424 (DB17357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an intravenous (IV) infusion.
Study: NCT05144256
Drug: Mitapivat
Normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets or granules
Study: NCT05144256
Drug: Mitapivat-matching placebo
Normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets or granules
Study: NCT06166654
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.
Study: NCT06166654
Drug: Metolazone 2.5 MG
Normalized name: metolazone 2.5 MG
DrugBank: Metolazone (DB00524)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2. 2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.
Study: NCT05458297
Drug: Nemtabrutinib
Normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05254743
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05254743
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT05707377
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib capsules administered orally.
Study: NCT05707377
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus capsules administered orally.
Study: NCT06568939
Drug: Telisotuzumab Vedotin
Normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT06786520
Drug: CAB LA
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAB LA injection will be administered
Study: NCT06786520
Drug: CAB ULA
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAB ULA injection will be administered
Study: NCT06165341
Drug: Fazirsiran Injection
Normalized name: Fazirsiran
DrugBank: Fazirsiran (DB17891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazirsiran will be injected subcutaneously.
Study: NCT05767021
Drug: Mirikizumab
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT05767021
Drug: Mirikizumab
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05446480
Drug: Desloratadine
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ingestion 10mg pill 2 hours prior to heat strain trial. Second 10mg dose 24-hours later.
Study: NCT05570994
Drug: 177Lu HTK03170
Normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 177Lu HTK03170 treatment over 5 cycles, each cycle occurs every 8 weeks.
Study: NCT05570994
Drug: 68Ga-HTK03149
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-HTK03149 PET/CT imaging; intravenous during screening
Study: NCT06486662
Drug: OM-85-IN
Normalized name: Sudafed OM
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of OM-85-IN
Study: NCT05072093
Drug: Offering of STI PEP
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All men in the cohort will be offered STI PEP (doxycycline) to use after condomless sex with the goal of averting STI diagnoses. At a dosage of 200 mg to be taken in a single dose ideally within 24 hours of possible exposure (e.g. condomless anal sex) and no later than 72 hours after exposure. Participants will be dispensed enough pills to allow for up to 3 weekly doses of 200mg doxycycline (i.e. 6 pills/week) for 3 months (the interval between STI testing visits).
Study: NCT05072093
Drug: Injectable PrEP
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For men who are interested in injectable PrEP, they will be referred to local providers to access Apretude (Cabotegravir injection) every two months. In the study, their use of the medication will be monitored through monthly surveys during which they have the option to indicate interest in switching to oral PrEP.
Study: NCT05569382
Drug: Verapamil
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration
Study: NCT05569382
Drug: Bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration
Study: NCT04771520
Drug: Avapritinib
Normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05904496
Drug: BGB-30813
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose administered on specified days
Study: NCT05904496
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose administered on specified days
Study: NCT06528496
Drug: Cytoxan
Normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is an alkylating agent related to nitrogen mustard
Study: NCT06528496
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan is a topoisomerase I-inhibitor that is a semisynthetic derivative of camptothecin.
Study: NCT06528496
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine is an alkaloid isolated from Vinca rosea Linn (periwinkle).
Study: NCT06528496
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide is a structural analogue of cyclophosphamide
Study: NCT06528496
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide for Injection is available as a 20 mg/mL solution in sterile multiple dose vials (5 mL, 25 mL, or 50 mL each).
Study: NCT06528496
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is available in 50 mg, 150 mg, 450 mg, and 600 mg vials.
Study: NCT06528496
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan hydrochloride trihydrate (CPT-11) is a topoisomerase I inhibitor
Study: NCT06528496
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide is administered intravenously
Study: NCT05875974
Drug: JZP258 (XYWAV)
Normalized name: Xywav
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiate dosage per study protocol and titrate to variable dosage.
Study: NCT05006716
Drug: BGB-16673
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered